{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:00:10Z","timestamp":1793829610740,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan Institute for Health Security"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03759-1","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:20:31Z","timestamp":1788668431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Longitudinal Treatment Outcomes for Patients with Metastatic Castration-Sensitive Prostate Cancer in Japan"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-2874","authenticated-orcid":false,"given":"Taketo","family":"Kawai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Kiyonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"3759_CR1","unstructured":"Foundation for Promotion of Cancer Research. Cancer Statistics in Japan \u2013 2023. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/pdf\/cancer_statistics_2023.pdf. Accessed 7 April 2026."},{"issue":"6","key":"3759_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17061013","volume":"17","author":"LC Ko","year":"2025","unstructured":"Ko LC, Gravina N, Berghausen J, Abdo J. Rising trends in prostate cancer among Asian men: global concerns and diagnostic solutions. Cancers (Basel). 2025;17(6):1013. https:\/\/doi.org\/10.3390\/cancers17061013.","journal-title":"Cancers (Basel)"},{"key":"3759_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/rru.S303215","volume":"14","author":"E Choi","year":"2022","unstructured":"Choi E, Buie J, Camacho J, Sharma P, de Riese WTW. Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers. Res Rep Urol. 2022;14:87\u2013108. https:\/\/doi.org\/10.2147\/rru.S303215.","journal-title":"Res Rep Urol"},{"issue":"1","key":"3759_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-93136-9","volume":"15","author":"M Shiota","year":"2025","unstructured":"Shiota M, Liu Y, Mundle S, et al. The impact of androgen receptor pathway inhibitors as starting treatment in metastatic castration-sensitive prostate cancer on patient outcomes (OASIS Japan). Sci Rep. 2025;15(1):13598. https:\/\/doi.org\/10.1038\/s41598-025-93136-9.","journal-title":"Sci Rep"},{"issue":"1","key":"3759_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5526-3","volume":"19","author":"T Iguchi","year":"2019","unstructured":"Iguchi T, Tamada S, Kato M, Yasuda S, Yamasaki T, Nakatani T. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase\u00a0II trial (the OCUU-CRPC study). BMC Cancer. 2019;19(1):339. https:\/\/doi.org\/10.1186\/s12885-019-5526-3.","journal-title":"BMC Cancer"},{"issue":"4","key":"3759_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jjco\/hyae177","volume":"55","author":"T Kimura","year":"2025","unstructured":"Kimura T, Ito T, Taguchi T, Hattori K, Matsuyama R. Initial treatment and resource utilization among patients with metastatic-castration sensitive prostate cancer in Japan: a retrospective real-world study. Jpn J Clin Oncol. 2025;55(4):399\u2013405. https:\/\/doi.org\/10.1093\/jjco\/hyae177.","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"3759_CR7","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1007\/s10147-022-02221-w","volume":"27","author":"H Uemura","year":"2022","unstructured":"Uemura H, Kobayashi K, Yokomizo A, et al. Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study. Int J Clin Oncol. 2022;27(10):1632\u201343. https:\/\/doi.org\/10.1007\/s10147-022-02221-w.","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"3759_CR8","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/jjco\/hyaf061","volume":"55","author":"M Onozawa","year":"2025","unstructured":"Onozawa M, Kawai T, Hinotsu S, et al. Patient characteristics, treatment patterns, and survival outcomes in patients with castration-resistant prostate cancer: results from the J-CaP registry. Jpn J Clin Oncol. 2025;55(7):816\u201324. https:\/\/doi.org\/10.1093\/jjco\/hyaf061.","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"3759_CR9","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.21873\/anticanres.14431","volume":"40","author":"Y Shimura","year":"2020","unstructured":"Shimura Y, Suga Y, Itai S, et al. Comparison of tolerability between 2-weekly and 3-weekly docetaxel regimen in castration-resistant prostate cancer. Anticancer Res. 2020;40(8):4291\u20137. https:\/\/doi.org\/10.21873\/anticanres.14431.","journal-title":"Anticancer Res"},{"issue":"1","key":"3759_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.21873\/invivo.12268","volume":"35","author":"Y Miyazawa","year":"2021","unstructured":"Miyazawa Y, Sekine Y, Arai S, et al. Prognostic factors in hormone-sensitive prostate cancer patients treated with combined androgen blockade: a consecutive 15-year study at a single Japanese institute. In Vivo. 2021;35(1):373\u201384. https:\/\/doi.org\/10.21873\/invivo.12268.","journal-title":"In Vivo"},{"issue":"4","key":"3759_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1702900.","journal-title":"N Engl J Med"},{"issue":"2","key":"3759_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1903835.","journal-title":"N Engl J Med"},{"issue":"1","key":"3759_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307.","journal-title":"N Engl J Med"},{"issue":"11","key":"3759_CR14","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/iju.15545","volume":"31","author":"Y Kohjimoto","year":"2023","unstructured":"Kohjimoto Y, Uemura H, Yoshida M, et al. Japanese clinical practice guidelines for prostate cancer 2023. Int J Urol. 2023;31(11):1180\u2013222. https:\/\/doi.org\/10.1111\/iju.15545.","journal-title":"Int J Urol"},{"key":"3759_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s12325-025-03437-8","volume":"43","author":"T Kawai","year":"2025","unstructured":"Kawai T, Kiyonaga F, Shibata H, Tanaka Y, Saito A. Real-world treatment patterns in patients with metastatic castration-sensitive prostate cancer in Japan: a retrospective health administrative data analysis. Adv Ther. 2025;43:390\u2013406. https:\/\/doi.org\/10.1007\/s12325-025-03437-8.","journal-title":"Adv Ther"},{"key":"3759_CR16","unstructured":"Medical Data Vision Co., Ltd. MDV Database Overview. https:\/\/en.mdv.co.jp\/ebm\/about-mdv-database\/mdv-database-overview\/. Accessed 1 June 2026."},{"issue":"2","key":"3759_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","volume":"9","author":"T Laurent","year":"2022","unstructured":"Laurent T, Simeone J, Kuwatsuru R, et al. Context and considerations for use of two Japanese real-world databases in Japan: Medical Data Vision and Japanese Medical Data Center. Drugs. 2022;9(2):175\u201387. https:\/\/doi.org\/10.1007\/s40801-022-00296-5.","journal-title":"Drugs"},{"issue":"1","key":"3759_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-022-00979-9","volume":"22","author":"A Leith","year":"2022","unstructured":"Leith A, Ribbands A, Kim J, et al. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan. BMC Urol. 2022;22(1):33. https:\/\/doi.org\/10.1186\/s12894-022-00979-9.","journal-title":"BMC Urol"},{"issue":"15_suppl","key":"3759_CR19","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.1200\/JCO.2021.39.15_suppl.5072","volume":"39","author":"U Swami","year":"2021","unstructured":"Swami U, Hong A, El-Chaar NN, et al. Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database. J Clin Oncol. 2021;39(15_suppl):5072. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.5072.","journal-title":"J Clin Oncol"},{"issue":"24","key":"3759_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70226","volume":"13","author":"H Miura","year":"2024","unstructured":"Miura H, Yamamoto H, Okuyama Y, et al. Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. Cancer Med. 2024;13(24):e70226. https:\/\/doi.org\/10.1002\/cam4.70226.","journal-title":"Cancer Med"},{"issue":"10336","key":"3759_CR21","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/s0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase\u00a03 study with a 2\u2009\u00d7\u20092 factorial design. Lancet. 2022;399(10336):1695\u2013707. https:\/\/doi.org\/10.1016\/s0140-6736(22)00367-1.","journal-title":"Lancet"},{"issue":"12","key":"3759_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2119115.","journal-title":"N Engl J Med"},{"issue":"4","key":"3759_CR23","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.3390\/curroncol30040332","volume":"30","author":"A Mittal","year":"2023","unstructured":"Mittal A, Sridhar SS, Ong M, Jiang DM. Triplet therapy in metastatic castrate sensitive prostate cancer (mCSPC)-a potential new standard of care. Curr Oncol. 2023;30(4):4365\u201378. https:\/\/doi.org\/10.3390\/curroncol30040332.","journal-title":"Curr Oncol"},{"issue":"9","key":"3759_CR24","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/iju.15498","volume":"31","author":"H Watanabe","year":"2024","unstructured":"Watanabe H, Nakane K, Takahara K, et al. Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor. Int J Urol. 2024;31(9):986\u201393. https:\/\/doi.org\/10.1111\/iju.15498.","journal-title":"Int J Urol"},{"issue":"2","key":"3759_CR25","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.clgc.2023.12.018","volume":"22","author":"M Kafka","year":"2024","unstructured":"Kafka M, Giannini G, Artamonova N, et al. Real-world evidence of triplet therapy in metastatic hormone-sensitive prostate cancer: an Austrian multicenter study. Clin Genitourin Cancer. 2024;22(2):458-466.e451. https:\/\/doi.org\/10.1016\/j.clgc.2023.12.018.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"3759_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/pros.24813","volume":"85","author":"T Yanagisawa","year":"2025","unstructured":"Yanagisawa T, Fukuokaya W, Hatakeyama S, et al. Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: a multicenter study. Prostate. 2025;85(2):165\u201374. https:\/\/doi.org\/10.1002\/pros.24813.","journal-title":"Prostate"},{"issue":"5","key":"3759_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102140","volume":"22","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Shiraishi Y, Furukawa J, et al. Clinical outcomes and risk stratification in patients with metastatic hormone-sensitive prostate cancer treated with new-generation androgen receptor signaling inhibitors. Clin Genitourin Cancer. 2024;22(5):102140. https:\/\/doi.org\/10.1016\/j.clgc.2024.102140.","journal-title":"Clin Genitourin Cancer"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03759-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03759-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03759-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T16:02:37Z","timestamp":1788710557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03759-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":27,"alternative-id":["3759"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03759-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Taketo Kawai reports receiving research funding and consulting fees from Astellas Pharma, and honoraria from Astellas Pharma, Merck Biopharma, and Sanofi. Fumiko Kiyonaga, Satoshi Uno, Hirotaka Shibata, and Atsushi Saito are employees of Astellas Pharma Inc, the sponsor of this study.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Medical Affairs Protocol Review Committee of Astellas Pharma Inc. This study was conducted in accordance with the protocol, International Council for Harmonisation guidelines, applicable regulations and guidelines governing clinical study conduct, and the Declaration of Helsinki 1964 and its later amendments. As the dataset was anonymized for secondary use, the requirements for ethical approval and informed consent did not apply to this study, as specified by Japan\u2019s Ethical Guidelines for Medical and Biological Research Involving Human Subjects. Data were purchased from MDV after obtaining the necessary permissions, and authors had permission from the database owners to access and use the database for this study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}